This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Maximum Plasma Concentration (Cmax) of ABBV-932
Timeframe: Up to approximately 6 days
Time to Cmax (Tmax) of ABBV-932
Timeframe: Up to approximately 6 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-932
Timeframe: Up to approximately 6 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932
Timeframe: Up to approximately 6 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932
Timeframe: Up to approximately 6 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932
Timeframe: Up to approximately 6 days
Number of Participants Experiencing Adverse Events
Timeframe: Up to approximately 180 days